An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Tamura, Tomohide [1 ]
Nishio, Makoto [2 ]
Yamamoto, Nobuyuki [3 ]
Ohe, Yuichiro [1 ]
Wolff, Katharina [4 ]
Tsujimoto, Mika [5 ]
Enatsu, Sotaro [4 ]
Nakagawa, Kazuhiko [6 ]
机构：
[1] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
[2] Canc Inst Hosp Jfcr, Thorac Med Oncol, Tokyo, Japan
[3] Wakayama Med Univ Hosp, Med Oncol, Wakayama, Japan
[4] Eli Lilly Japan, Med Sci, Kobe, Hyogo, Japan
[5] Eli Lilly Japan, Stat Sci, Kobe, Hyogo, Japan
[6] Kinki Univ, Fac Med, Med Oncol, Osaka, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
gemcitabine-cisplatin; necitumumab; squamous non-small cell lung cancer; trial in progress;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-080
引用
收藏
页码：S664 / S665
页数：2
相关论文
共 50 条
  • [21] Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Butts, C. A.
    Bodkin, D.
    Middleman, E. L.
    Englund, C. W.
    Ellison, D.
    Alam, Y. Z.
    Pautret, V.
    Weber, M.
    Kreisman, H.
    Shepherd, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] A phase II study of biweekly carboplatin (Cb) and gemcitabine (G) with bevacizumab (B) as first-line treatment in patients with advanced, inoperable stage IIIb/IV non-squamous non-small cell lung cancer (NSCLC)
    Bommakanti, S.
    Larson, T.
    Dudek, A.
    Koopmeiners, J.
    Kumar, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Biweekly cisplatin and gemcitabine as first line treatment in stage IV non-small cell lung cancer
    Gunaydin, Y.
    Benekli, M.
    Inanc, M.
    Ozkan, M.
    Demirci, A.
    Demirci, U.
    Suner, A.
    Karaca, H.
    Berk, V.
    Buyukberber, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S832 - S832
  • [24] Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR-Expressing Squamous Non-Small-Cell Lung Cancer German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)
    Reck, Martin
    Thomas, Michael
    Kropf-Sanchen, Cornelia
    Mezger, Joerg
    Socinski, Mark A.
    Depenbrock, Henrik
    Soldatenkova, Victoria
    Brown, Jacqueline
    Krause, Thomas
    Thatcher, Nick
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (09) : 539 - 547
  • [25] Gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC as first-line treatment for stage IV squamous cell lung cancer (SqCLC): An open-label randomized multicenter phase Ib-II trial in Japan.
    Yoshioka, Hiroshige
    Watanabe, Satoshi
    Sakai, Hiroshi
    Hotta, Katsuyuki
    Takenoyama, Mitsuhiro
    Yamada, Kazuhiko
    Sugawara, Shunichi
    Takiguchi, Yuichi
    Hosomi, Yukio
    Tomii, Keisuke
    Niho, Seiji
    Yamamoto, Nobuyuki
    Nishio, Makoto
    Ohe, Yuichiro
    Kamada, Ami
    Suzukawa, Kazumi
    Omori, Yukie
    Enatsu, Sotaro
    Nakagawa, Kazuhiko
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer
    Villaruz, Liza C.
    Cobo, Manuel
    Syrigos, Konstantinos
    Mavroudis, Dimitrios
    Zhang, Wei
    Kim, Jong Seok
    Socinski, Mark A.
    LUNG CANCER, 2019, 136 : 52 - 56
  • [27] Docetaxel in combination with Gemcitabine as first-line treatment of patients with inoperable, locally advanced or metastatic non-small cell lung cancer (NSCLC)
    Barata, Fernando
    Sousa, Amelia
    Camacho, Elvira
    Costa, Marco S.
    Canario, Dolores
    Nogueira, Fernando
    Semedo, Eulalia
    ANNALS OF ONCOLOGY, 2004, 15 : 179 - 179
  • [28] DHA-paclitaxel (Taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: Report of a phase II open-label multicenter trial
    Payne, Miranda
    Ellis, Paul
    Dunlop, David
    Ranson, Malcolm
    Danson, Sarah
    Schacter, Lee
    Talbot, Denis
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (09) : 984 - 990
  • [29] A nonrandomized, multicenter, phase II study of S-1 with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC)
    Jones, D. V.
    Zergebel, C.
    Saito, K.
    Sandler, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)
    Paz-Ares, L.
    Socinski, M. A.
    Shahidi, J.
    Hozak, R. R.
    Soldatenkova, V.
    Thatcher, N.
    Hirsch, F.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S153 - S153
12345